BUHLMANN Diagnostics Corp. Announces New Distribution Agreement With Meridian Biosciences, Inc.
Uploaded by
PR.comBUHLMANN Diagnostics Corp. Announces New Distribution Agreement With Meridian Biosciences, Inc.
Uploaded by
PR.comBUHLMANN Diagnostics Corp.
Announces New Distribution Agreement with
Meridian Biosciences, Inc.
BUHLMANN Diagnostics Corp. has embarked on a new partnership with Meridian Bioscience, Inc.
for the distribution of the 510(k) cleared, BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay
intended for the quantitation of calprotectin in human stool.
Amherst, NH, January 31, 2019 --(PR.com)-- BUHLMANN Diagnostic Corp. (BDC), Amherst, NH is
proud to announce they have entered into a distribution agreement with Meridian Bioscience, Inc.,
Cincinnati, Ohio to market the FDA-cleared BÜHLMANN fCAL® ELISA for the quantitative
measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in the
diagnosis of inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis
(UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other
laboratory and clinical findings.
This partnership reflects BDC's commitment to diagnostics and aim to expand reach to laboratories across
the country. This collaboration also aligns with Meridian's continuing efforts to deepen their GI product
portfolio and extend their offerings to clinical laboratories, including Health System and Integrated
Delivery Networks who look to standardize and optimize patient care.
BDC CEO, Doug Olson commented, “Today's announcement is another great example of our efforts to
support the gastroenterology field. Our partnership with Meridian is an important step in our collective
goal of improving patient care by providing a quality fecal calprotectin assay with timely, accurate results
to aid patient management.”
Visit www.buhlmannlabs.com to learn more about this assay, and overall performance.
About BÜHLMANN Laboratories AG
Founded in 1976, BÜHLMANN Laboratories AG has continued to focus on growing a product portfolio
of in vitro diagnostics and research markets. BÜHLMANN is known for outstanding product quality,
providing excellent after-sales services, and delivering remarkable scientific innovations. BÜHLMANN
offers the broadest range of calprotectin products as well as a selection of unique, high-quality assays
such as the BÜHLMANN Flow CAST® product group for Basophil Activation Testing, the
BÜHLMANN GanglioCombi™ products for neuroimmunology, and a variety of Melatonin Assays.
About BUHLMANN Diagnostics Corp (BDC)
BUHLMANN Diagnostics Corp (BDC) is the North American affiliate of BÜHLMANN Laboratories
AG, the worldwide provider of ELISA kits, RIA kits, lateral flow and flow cytometry assays. Located in
Southern New Hampshire, BDC has a highly experienced team who represent a breadth of experience in
serving both clinical and basic science research laboratories.
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a
Page 1/3
PR.com Press Release Distribution Terms of Use
broad range of innovative diagnostic products. We are dedicated to developing and delivering better
solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life
from discovery to diagnosis. Through discovery and development, we provide critical life science raw
materials used in immunological and molecular tests for human, animal, plant, and environmental
applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and
upper respiratory infections and blood lead level testing. We build relationships and provide solutions to
hospitals, reference laboratories, research centers, veterinary testing centers, physician offices,
diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
About BÜHLMANN Calprotectin Product Line
The calprotectin portfolio consists of the BÜHLMANN fCAL® ELISA (FDA 510(k) cleared),
BÜHLMANN fCAL® turbo for testing on most clinical chemistry analyzers (RUO in the US), Quantum
Blue® fCAL Rapid Test (RUO in the US), and IBDoc®, the first and only Health Canada Licensed
home-testing application for fecal calprotectin in IBD patients (IBDoc® not available for sale in the US).
Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
BUHLMANN Diagnostics Corp
Stacy Smith
844-300-9799
Contact via Email
www.buhlmannlabs.com
[email protected]
Online Version of Press Release:
You can read the online version of this press release at: https://www.pr.com/press-release/775833
News Image:
Page 3/3
PR.com Press Release Distribution Terms of Use
